Free Trial Information
BioCentury | Jan 1, 2021
Deals

The good, the bad and the COVID: BioCentury’s playlist for pandemic times

Saying goodbye to a grueling year, BioCentury editors have furrowed among the disasters to pick out some of the positives from 2020, and call out some of the worst of the pandemic’s collateral damage....
Read More
BioCentury | Dec 30, 2020
Product Development

Regeneron finds enough signal to continue testing COVID-19 antibody cocktail in subset of hospitalized patients

Data announced by Regeneron Tuesday carves out a potential window for COVID-19 mAb therapies in hospitalized patients, an indication where mAbs from the company and its competitors have yet to prove out. Regeneron Pharmaceuticals Inc....
Read More
BioCentury | Nov 12, 2020
Product Development

COVID mAb data from Lilly, AbCellera suggest monotherapy may soon be superseded by Lilly’s combo

Whether the spike-targeting mAb bamlanivimab from Eli Lilly and AbCellera will have a substantial impact on the COVID-19 pandemic boils down to two factors: the strength of its efficacy and its availability....
Read More
BioCentury | Nov 11, 2020
Product Development

Operation Warp Speed defends dosing for Lilly mAb, outlines distribution strategy

Trump administration officials Tuesday dismissed concerns that FDA may have authorized an ineffective dose of Lilly’s COVID-19 mAb and expressed confidence that bamlanivimab will have a substantial impact...
Read More
BioCentury | Nov 10, 2020
Finance

Nov. 9 Quick Takes: Biogen sheds $14B in value; plus Ambrx’s 200M round, Decibel’s series D and more

...The data showed that the therapy did not lead to a meaningful rate of sustained virologic...
Read More
BioCentury | Oct 28, 2020
Deals

Supply constraints loom as Regeneron reports positive data on COVID-19 mAb

...cocktail from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) met the study’s first nine endpoints. In addition to meeting virologic...
...on an additional 524 patients in the Phase II/III study. The first nine endpoints evaluated virologic...
...changes to dosing in the ongoing outpatient clinical trial due to the limited supply of REGN-COV2.Virologic...
Read More
BioCentury | Oct 24, 2020
Regulation

Advice now, consent later, on COVID-19 vaccines

FDA’s Oct. 22 vaccines advisory committee meeting was principally intended to reassure the public that career staff will make decisions about COVID-19 vaccines and will not be influenced by political preferences or timetables. A second...
Read More
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

As targeted protein degradation grows up, the field is going after harder targets and new mechanisms of action. Over the last year, a series of Phase I/II readouts from front-runner Arvinas Inc. (NASDAQ:ARVN),...
Read More
BioCentury | Oct 15, 2020
Product Development

Oct. 14 Quick Takes: FDA approves first Ebola therapy; plus Vertex tumbles after hours on AAT discontinuation

Regeneron’s Ebola mAb cocktail approvedFDA approved Inmazeb atoltivimab/maftivimab/odesivimab-ebgn from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to treat Zaire ebolavirus infection. The mAb cocktail had raised the chance of survival vs. ZMapp, a mAb combination used as a control, in...
Read More
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

Rachel Humphrey has joined Black Diamond Therapeutics Inc. (NASDAQ:BDTX) as CMO. Karsten Witt, who has been SVP of clinical development and acting CMO since May 2019, will become SVP of non-clinical development. Previously, Humphrey was...
Read More
Items per page:
1 - 10 of 1615
BioCentury | Jan 1, 2021
Deals

The good, the bad and the COVID: BioCentury’s playlist for pandemic times

Saying goodbye to a grueling year, BioCentury editors have furrowed among the disasters to pick out some of the positives from 2020, and call out some of the worst of the pandemic’s collateral damage....
Read More
BioCentury | Dec 30, 2020
Product Development

Regeneron finds enough signal to continue testing COVID-19 antibody cocktail in subset of hospitalized patients

Data announced by Regeneron Tuesday carves out a potential window for COVID-19 mAb therapies in hospitalized patients, an indication where mAbs from the company and its competitors have yet to prove out. Regeneron Pharmaceuticals Inc....
Read More
BioCentury | Nov 12, 2020
Product Development

COVID mAb data from Lilly, AbCellera suggest monotherapy may soon be superseded by Lilly’s combo

Whether the spike-targeting mAb bamlanivimab from Eli Lilly and AbCellera will have a substantial impact on the COVID-19 pandemic boils down to two factors: the strength of its efficacy and its availability....
Read More
BioCentury | Nov 11, 2020
Product Development

Operation Warp Speed defends dosing for Lilly mAb, outlines distribution strategy

Trump administration officials Tuesday dismissed concerns that FDA may have authorized an ineffective dose of Lilly’s COVID-19 mAb and expressed confidence that bamlanivimab will have a substantial impact...
Read More
BioCentury | Nov 10, 2020
Finance

Nov. 9 Quick Takes: Biogen sheds $14B in value; plus Ambrx’s 200M round, Decibel’s series D and more

...The data showed that the therapy did not lead to a meaningful rate of sustained virologic...
Read More
BioCentury | Oct 28, 2020
Deals

Supply constraints loom as Regeneron reports positive data on COVID-19 mAb

...cocktail from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) met the study’s first nine endpoints. In addition to meeting virologic...
...on an additional 524 patients in the Phase II/III study. The first nine endpoints evaluated virologic...
...changes to dosing in the ongoing outpatient clinical trial due to the limited supply of REGN-COV2.Virologic...
Read More
BioCentury | Oct 24, 2020
Regulation

Advice now, consent later, on COVID-19 vaccines

FDA’s Oct. 22 vaccines advisory committee meeting was principally intended to reassure the public that career staff will make decisions about COVID-19 vaccines and will not be influenced by political preferences or timetables. A second...
Read More
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

As targeted protein degradation grows up, the field is going after harder targets and new mechanisms of action. Over the last year, a series of Phase I/II readouts from front-runner Arvinas Inc. (NASDAQ:ARVN),...
Read More
BioCentury | Oct 15, 2020
Product Development

Oct. 14 Quick Takes: FDA approves first Ebola therapy; plus Vertex tumbles after hours on AAT discontinuation

Regeneron’s Ebola mAb cocktail approvedFDA approved Inmazeb atoltivimab/maftivimab/odesivimab-ebgn from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to treat Zaire ebolavirus infection. The mAb cocktail had raised the chance of survival vs. ZMapp, a mAb combination used as a control, in...
Read More
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

Rachel Humphrey has joined Black Diamond Therapeutics Inc. (NASDAQ:BDTX) as CMO. Karsten Witt, who has been SVP of clinical development and acting CMO since May 2019, will become SVP of non-clinical development. Previously, Humphrey was...
Read More
Items per page:
1 - 10 of 1615